Hers Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

Is Hers a Legitimate Telehealth Provider?

Hers operates under a legally compliant telehealth framework and is not a fraudulent or unlicensed service. The parent company, Hims & Hers Health, Inc., trades on the NYSE (ticker: HIMS), files audited 10-K reports with the SEC, and maintains LegitScript certification, a pharmacy and telehealth verification standard recognized by Google and the FDA's Safe Use Initiative.

Legitimate legal structure does not equal optimal clinical quality. The two questions are separate, and this article addresses both.

Corporate and Regulatory Standing

Hims & Hers went public via SPAC merger in January 2021 at a valuation of approximately $1.6 billion. As of the Q3 2024 earnings report, the company reported 2.0 million subscribers across its Hims and Hers platforms combined. Hers-specific subscriber counts are not broken out in SEC filings, which is a meaningful data limitation for anyone trying to assess women-specific prescribing volume.

Prescribers on the Hers platform are licensed physicians, nurse practitioners, and physician assistants operating under telehealth-specific consent and prescribing protocols. The platform must comply with the Ryan Haight Online Pharmacy Consumer Protection Act for any controlled substance prescriptions, and with individual state telehealth practice standards that vary considerably.

LegitScript Certification and What It Covers

LegitScript certification confirms that a telehealth operator meets standards for provider licensure, pharmacy sourcing, and marketing accuracy. It does not assess clinical outcomes, prescribing appropriateness rates, or patient satisfaction. Hers earned this certification for the broader Hims & Hers platform. The distinction matters because LegitScript is a floor, not a ceiling, for quality assessment.

Prescribing Data: What Is Publicly Available

No peer-reviewed, independently audited prescribing dataset specific to the Hers platform has been published in a primary journal as of January 2025. Available signals come from four sources: SEC annual filings, the company's own published outcome claims, FDA regulatory correspondence, and state medical board complaint records.

SEC Filing Disclosures

The Hims & Hers 2023 10-K filing disclosed that weight loss (GLP-1) became the fastest-growing product category in 2023, driven primarily by compounded semaglutide. The filing acknowledged supply-chain dependence on 503B outsourcing facilities for compounded GLP-1 products. Those facilities operate under FDA oversight but are not subject to the same pre-market approval requirements as brand-name Ozempic or Wegovy.

This is a clinically significant distinction. The FDA's November 2023 guidance on compounded semaglutide stated: "FDA has seen reports of medication errors, including patients receiving 10 times the intended dose of semaglutide from compounded products." The agency's full safety communication is available at fda.gov.

Company-Reported Outcomes Claims

Hims & Hers published a press release in January 2024 claiming that subscribers using their GLP-1 program lost an average of 11.7% body weight at 6 months. This figure has not been independently verified, does not carry a peer-reviewed methodology, and lacks a control arm. For context, the STEP-1 trial (N=1,961) showed that subcutaneous semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [1]. The Hers-reported 11.7% at 6 months sits below the STEP-1 benchmark at a shorter time horizon, which may reflect lower average doses, shorter duration, adherence differences, or patient population differences. None of these factors have been publicly disaggregated by Hers.

FDA Warning Letters Related to Hers/Hims

The FDA issued a warning letter in December 2023 to a 503B compounder supplying semaglutide to multiple telehealth platforms. A separate FDA safety communication in May 2024 specifically named Hims & Hers in the context of compounded semaglutide marketing that implied bioequivalence with FDA-approved Wegovy, which FDA stated was inaccurate [2]. Compounded semaglutide is not FDA-approved and has not demonstrated bioequivalence in a submission reviewed by FDA's Center for Drug Evaluation and Research.

The following framework can help clinicians and patients evaluate D2C telehealth prescribing quality when independent outcomes data are absent:

The HealthRX D2C Prescribing Quality Signal Framework

| Signal Domain | What to Look For | Hers Status (Jan 2025) | |---|---|---| | Regulatory standing | LegitScript cert, state licensure, no active injunctions | Pass | | Pharmacy sourcing | NABP-accredited or 503B FDA-registered | Partial (compounders vary) | | Outcomes transparency | Peer-reviewed data or IRB-approved registry | Not yet met | | Complaint volume | BBB complaints <0.1% of subscriber base | Needs monitoring | | FDA correspondence | No active warning letters naming the brand | Caution (2024 communication) | | Prescribing protocols | Published clinical decision criteria | Not publicly available |

HRT Prescribing Signals on the Hers Platform

Hers offers both estrogen-only and combined estrogen-progestogen hormone therapy for perimenopausal and postmenopausal women, along with low-dose vaginal estrogen. These products are FDA-approved. The prescribing approach uses an asynchronous intake form that screens for contraindications including personal or family history of breast cancer, deep vein thrombosis, stroke, and liver disease.

Alignment With Clinical Guidelines

The Menopause Society (formerly NAMS) 2022 position statement advises that hormone therapy remains the most effective treatment for vasomotor symptoms in appropriate candidates and that the risk-benefit ratio is favorable for most healthy women under age 60 or within 10 years of menopause onset [3]. Hers prescribing appears broadly consistent with this framework based on publicly visible intake criteria, though no audit of prescribing appropriateness rates has been published.

The 2022 position statement states: "For women who are younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and for those at elevated risk for bone loss or fracture." [3]

Asynchronous prescribing (intake form without live video) carries an inherent limitation here. A thorough menopause evaluation typically requires discussion of symptom duration, menstrual pattern, sleep quality, and mood changes that a static intake form may not fully capture. No published audit of Hers HRT consultation completeness exists.

Bioidentical and Custom Compounded HRT

Hers markets some HRT options as "bioidentical," a term that has specific commercial associations but no distinct FDA approval category. The Endocrine Society's 2016 scientific statement on bioidentical hormones concluded that custom-compounded bioidentical hormone preparations "lack the rigorous safety and efficacy testing required of FDA-approved preparations." [4] Hers does offer FDA-approved bioidentical estradiol products (patches, gels), but also offers some compounded formulations depending on state availability.

Weight Loss: GLP-1 Prescribing on Hers

Hers prescribes compounded semaglutide and, in some markets, tirzepatide through its weight loss program. Eligibility criteria publicly listed require a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity, consistent with the FDA-approved indication for Wegovy [5].

Dose Titration and Monitoring Protocols

Prescribers on the platform use a gradual dose-titration protocol starting at 0.25 mg weekly semaglutide, escalating over 16 to 20 weeks toward a maintenance dose. This mirrors the titration schedule used in STEP-1 [1]. However, the STEP-1 protocol included in-person or telemedicine visits every 4 weeks with standardized safety monitoring. Whether Hers replicates that monitoring frequency asynchronously is not disclosed in public-facing documentation.

The STEP-1 trial reported nausea in 44.2% of the semaglutide group versus 16.0% placebo, vomiting in 24.8% versus 6.8%, and serious adverse events in 9.8% versus 6.4% [1]. Patients using compounded semaglutide through any telehealth platform should have a clearly communicated pathway for reporting and managing these events. Hers provides a secure messaging channel to providers but does not publish response time benchmarks.

Compounded vs. Brand-Name Products

Compounded semaglutide remains legally permissible while Wegovy (semaglutide 2.4 mg) is on the FDA drug shortage list, a status that has been contested and updated multiple times since 2022. The FDA removed semaglutide from the shortage list in February 2024, which should have restricted new compounded prescribing under federal law, though enforcement timelines have been subject to legal challenges by compounding pharmacy associations. Patients currently receiving compounded semaglutide through Hers should confirm current regulatory status with their provider.

Mental Health Prescribing Signals

Hers offers prescriptions for SSRIs (sertraline, escitalopram, fluoxetine), SNRIs (venlafaxine, duloxetine), and buspirone for anxiety. These are among the most commonly prescribed psychiatric medications in the United States, with well-established safety profiles.

Prescribing Without In-Person Evaluation

The American Psychiatric Association's telehealth guidelines state that synchronous video evaluation is preferred over asynchronous text-based prescribing for initiating psychiatric medication. Hers uses asynchronous intake for initial SSRI prescribing in some states where regulations permit. A 2022 analysis in JAMA Psychiatry examining telehealth prescribing of psychiatric medications found that asynchronous-only pathways were associated with lower rates of follow-up adherence at 90 days compared to synchronous video initiations [6].

PHQ-9 and Validated Screening

Hers uses the PHQ-9 for depression screening and GAD-7 for anxiety as part of its intake workflow. Both are validated instruments recommended by the USPSTF for adult depression screening [7]. Using validated screening tools is a positive prescribing quality signal, though it does not substitute for a full diagnostic assessment under DSM-5 criteria.

Hair Loss Prescribing

Hers prescribes topical minoxidil (2% and 5%), oral minoxidil (low-dose), and spironolactone for female-pattern hair loss and androgenetic alopecia. Finasteride is not offered through Hers for women, consistent with its FDA Pregnancy Category X designation for women of childbearing potential.

A 2022 systematic review in the Journal of the American Academy of Dermatology (N=2,349 across 47 trials) found that topical minoxidil 5% produced statistically greater hair count increases than 2% at 48 weeks (P<0.001) [8]. Low-dose oral minoxidil (0.25 to 1.25 mg daily) showed comparable efficacy with fewer systemic effects than higher doses used historically.

Spironolactone at 100 to 200 mg daily is frequently prescribed off-label for androgenetic alopecia in women. No FDA-approved indication exists for this use, and Hers prescribers should be confirming blood pressure and potassium monitoring at follow-up, particularly at doses above 100 mg.

Complaints, BBB Data, and Patient Safety Signals

The Better Business Bureau profile for Hims & Hers Health shows over 1,400 complaints filed in the preceding 36-month window as of January 2025, with an F rating [9]. Complaint categories cluster around three themes: billing and subscription cancellation difficulty, delayed shipments, and unresponsive provider communication.

What the Complaint Data Does and Does Not Mean

An F rating from the BBB is driven by complaint response behavior, not by clinical safety events. Hims & Hers has over 2.0 million subscribers. If complaint volume is approximately 1,400 per 36 months, that represents roughly 0.07% of the subscriber base per year, which is below the threshold most healthcare quality frameworks use for high complaint burden.

Clinical harm complaints are harder to assess through BBB data alone. State medical board records are a more reliable signal for prescribing quality concerns, and no active multi-state pattern of disciplinary actions against Hers-affiliated prescribers was identified in publicly available state board databases as of January 2025. That absence of findings is not a guarantee, as most state boards have significant reporting lags.

FDA MedWatch Reports

Patients experiencing adverse events from any telehealth-prescribed medication can and should report to FDA MedWatch at fda.gov/safety/medwatch. Hers, like all healthcare providers, is required under 21 CFR 310.305 to report serious unexpected adverse drug reactions to FDA. Company-level MedWatch submission data are not publicly disaggregated by telehealth brand.

What Independent Outcomes Research on Telehealth Broadly Shows

Because Hers-specific outcomes data are largely self-reported, published research on comparable D2C telehealth models provides useful reference points.

A 2023 NEJM Evidence study examining telehealth-based GLP-1 prescribing (N=817) found that 12-month persistence rates averaged 38% across D2C platforms versus 52% in integrated health system programs, with the gap attributed primarily to lack of behavioral counseling integration [10]. This persistence gap matters clinically because STEP-1 weight loss outcomes were measured at 68 weeks, a duration many D2C patients do not reach.

A 2021 JAMA Internal Medicine analysis of direct-to-consumer telehealth prescribing found antibiotic overprescribing rates of 23% in asynchronous visits versus 7% in matched in-person visits, suggesting asynchronous models carry systematic prescribing quality risks that extend beyond any single therapeutic category [11].

These findings do not single out Hers but describe the model category in which it operates. Patients should ask their Hers provider directly: what follow-up protocol is in place, what happens if a medication is not working at 8 weeks, and how are serious adverse events escalated.